These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 32554823)

  • 1. Painless thyroiditis in a dupilumab-treated patient.
    Narantsatsral D; Junko T; Hideyuki I; Daisuke I; Hiroyuki T; Yuka N; Syo H; Hiroyuki M; Kazuo O; Tetsuya O; Akiyoshi T
    Endocrinol Diabetes Metab Case Rep; 2020 Jun; 2020():. PubMed ID: 32554823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Prospective Study to Evaluate the Possible Role of Cholecalciferol Supplementation on Autoimmunity in Hashimoto's Thyroiditis.
    Bhakat B; Pal J; Das S; Charaborty SK; SircarMedical NR; Kolkata ; RGKar ; NorthBengal ; Siliguri
    J Assoc Physicians India; 2023 Jan; 71(1):1. PubMed ID: 37116030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperthyroidism in a 15-year-old adolescent treated with Dupilumab for severe allergic asthma and atopic dermatitis.
    Tosca MA; Olcese R; Girosi D; Casalini E; Scaglione M; Ciprandi G
    Allergol Immunopathol (Madr); 2023; 51(3):181-185. PubMed ID: 37169576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Destructive thyroiditis followed by hypothyroidism associated with infliximab therapy.
    Ozkan C; Altinova AE; Cerit ET; Yalcin MM; Toruner FB; Akturk M; Cakir N
    Endocr Pract; 2014 Nov; 20(11):e207-10. PubMed ID: 25100375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients.
    Guex-Crosier Y; Di-Lucca J; Häusermann P; Laffitte E; Saulite I; Schmid-Grendelmeier P; Schürch K; Thormann K; Simon D
    Swiss Med Wkly; 2021 Aug; 151():w30020. PubMed ID: 34495603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dupilumab side effect in a patient with atopic dermatitis: a case report study.
    Albader SS; Alharbi AA; Alenezi RF; Alsaif FM
    Biologics; 2019; 13():79-82. PubMed ID: 31190731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
    Blauvelt A; de Bruin-Weller M; Gooderham M; Cather JC; Weisman J; Pariser D; Simpson EL; Papp KA; Hong HC; Rubel D; Foley P; Prens E; Griffiths CEM; Etoh T; Pinto PH; Pujol RM; Szepietowski JC; Ettler K; Kemény L; Zhu X; Akinlade B; Hultsch T; Mastey V; Gadkari A; Eckert L; Amin N; Graham NMH; Pirozzi G; Stahl N; Yancopoulos GD; Shumel B
    Lancet; 2017 Jun; 389(10086):2287-2303. PubMed ID: 28478972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial.
    Thaçi D; Simpson EL; Beck LA; Bieber T; Blauvelt A; Papp K; Soong W; Worm M; Szepietowski JC; Sofen H; Kawashima M; Wu R; Weinstein SP; Graham NM; Pirozzi G; Teper A; Sutherland ER; Mastey V; Stahl N; Yancopoulos GD; Ardeleanu M
    Lancet; 2016 Jan; 387(10013):40-52. PubMed ID: 26454361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience.
    Sroka-Tomaszewska J; Bulińska B; Wilkowska A; Nowicki RJ; Trzeciak M
    Postepy Dermatol Alergol; 2023 Dec; 40(6):747-752. PubMed ID: 38282886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autoimmune hypothyroidism and subsequent hyperthyroidism by TSH receptor antibodies following subacute thyroiditis: a case report.
    Iitaka M; Kakinuma S; Yamanaka K; Fujimaki S; Oosuga I; Wada S; Katayama S
    Endocr J; 2001 Apr; 48(2):139-42. PubMed ID: 11456259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
    de Bruin-Weller M; Thaçi D; Smith CH; Reich K; Cork MJ; Radin A; Zhang Q; Akinlade B; Gadkari A; Eckert L; Hultsch T; Chen Z; Pirozzi G; Graham NMH; Shumel B
    Br J Dermatol; 2018 May; 178(5):1083-1101. PubMed ID: 29193016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of systemic lupus erythematosus after dupilumab treatment in a case of atopic dermatitis.
    Okune M; Okiyama N; Fukuzono M; Sasaki K; Nomura T
    J Dermatol; 2022 May; 49(5):556-559. PubMed ID: 35224748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of thyrotoxicosis-induced anemia in a patient with painless thyroiditis.
    Komiya I; Tomoyose T; Yagi N; Ouchi G; Wakugami T
    Thyroid Res; 2021 Apr; 14(1):9. PubMed ID: 33892761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of adult patients with atopic dermatitis treated with dupilumab: A single-center real-life experience.
    Su Küçük Ö; Güneş B; Taşlidere N; Işik BG; Akaslan TÇ; Özgen FP; Bahali AG
    J Cosmet Dermatol; 2022 Oct; 21(10):4781-4787. PubMed ID: 35038377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis.
    Ou Z; Chen C; Chen A; Yang Y; Zhou W
    Int Immunopharmacol; 2018 Jan; 54():303-310. PubMed ID: 29182975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.